|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Phase 2 TheraPb Trial Evaluates a Novel Induction and Maintenance Regimen of 212Pb-ADVC001 Across Three Metastatic Prostate Cancer Indications
|
Anna Karmann, MD, PhD
Anna Karmann outlines AdvanCell's Lead-212 alpha-emitting radioligand therapy program, covering the phase one experience and an emerging phase two design.
|
|
|
|
|
|
|
|
|
|
|
|
CIPHER Trial Investigates Carboplatin in mCRPC Patients with HRR Mutations
|
Atul Batra, MBBS, MD, DM
Neeraj Agarwal hosts Atul Batra to discuss the CIPHER trial, a single-center phase 2 study of carboplatin AUC5 every three weeks in 39 patients with metastatic castration-resistant prostate cancer harboring somatic or germline HRR gene mutations who had progressed on an ARPI, docetaxel, or both.
|
|
|
|
|
|
|
|
|
|
|
|
Working Group 4 Introduces Updated Terminology for Advanced Prostate Cancer
|
Andrew Armstrong, MD, MSc
Neeraj Agarwal speaks with Andrew Armstrong about the Prostate Cancer Working Group 4 consensus criteria and updated disease nomenclature. Dr. Armstrong explains that the terms castration-sensitive and castration-resistant have been replaced by androgen pathway modulator naive, sensitive, and resistant, applicable to any treatment, not just ADT.
|
|
|
|
|
|
|
|
|
|
|
| State of the Art Lecture: Why Are Germline and Somatic Alterations in Prostate Cancer Important?
|
| David Olmos, MD, PhD
|
| David Olmos emphasized that germline and somatic DNA repair alterations matter because they carry both prognostic and therapeutic significance in prostate cancer, especially for BRCA1/2-mutated disease, which behaves more aggressively across stages. He also highlighted that these findings affect not only treatment selection, including PARP inhibitor use, but also family counseling and genetic risk assessment, while the importance of many non-BRCA HRR alterations remains less certain.
|
|
|
|
|
|
|
|
|
|
|
| Integrating PARP Inhibitors in the Treatment of Prostate Cancer: Timing, Combination Approaches, and Beyond BRCA1/2
|
| Wassim Abida, MD, PhD
|
| Wassim Abida reviewed how PARP inhibitors are now standard for mCRPC with DNA damage repair alterations, especially BRCA1/2 and related genes such as PALB2. He emphasized that benefit is much less consistent in non-BRCA alterations like ATM, that PARP-ARPI combinations are effective in HRR-mutated first-line mCRPC, and that broader use outside DDR-mutated disease remains investigational.
|
|
|
|
|
|
| Imaging Meets Genomics in Treatment-Naïve Prostate Cancer: SUVmax on PSMA PET as a Biomarker of Genomic Classifier Risk
|
| Sophia Coraci
|
| In treatment-naïve prostate cancer, higher intraprostatic PSMA PET SUVmax was modestly associated with higher Decipher genomic risk, with SUVmax correlating better than PSA or PI-RADS. An SUVmax threshold of 15 was the best cutoff for identifying high-risk disease, suggesting PSMA PET may add noninvasive risk-stratification value alongside genomic testing.
|
|
|
|
|
|
| The Expanding Theranostic Dream: From Hype to Hard Truths
|
| Michael Hofman, MBBS
|
| Michael Hofman highlights both the promise and limitations of PSMA-targeted theranostics, noting that agents such as Lutetium-177 PSMA-617 can achieve meaningful PSA declines and tumor responses, but with variable durability and no clear overall survival advantage over cabazitaxel in the TheraP trial.
|
|
|
|
|
|
|
|
|
|
|
